Publications

Appraisal-specific

E Poku, J Rathbone, R Wong, E Everson-Hock, M Essat, A Pandor, A Wailoo. The safety of intravitreal bevacizumab monotherpay in adult ophthalmic conditions: systematic review. 2014 BMJ Open 4:e005244. DOI: 10.1136/bmjopen-2014-005244

A Wailoo, N Bansback, J Chilcott. Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: Cost-effectiveness evidence and NICE guidance: Reply Rheumatology 2008; Vol 47 (10): 1590.

A Wailoo, N Bansback, J Chilcott. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: Cost-effectiveness evidence and NICE guidance Rheumatology 2008; Vol 47 (2): 119-120.

A Wailoo, A Sutton, A Morgan. The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: A systematic review and meta-analysis 2009 British Journal of Cancer Vol 100: 436-441.

S Lloyd, S Bujkiewicz, A Wailoo, A Sutton, D Scott. The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: A systematic review and meta-analysis. Rheumatology 2010; Vol 49 (12): 2313-2321.

Methods development

Wailoo A, Bell Gorrod H, Dunning L, Kenny J, Leckenby E, Shah K. The NICE experience of designing and utilising severity weights. Health Policy OPEN, Volume 10, 2026, 100156, ISSN 2590-2296. DOI: https://doi.org/10.1016/j.hpopen.2025.100156

M Hernández Alava, SE Pudney, AJ Wailoo (2023). Does EQ-5D tell the whole story? Statistical methods for comparing the thematiccoverage of clinical and generic outcome measures, with application to breast cancer. Value in Health. DOI: https://doi.org/10.1016/j.jval.2023.05.016

A. Scope, A. Bhadhuri and B. Pennington (2022) "Systematic review of cost-utility analyses that have included carer and family member health-related quality of life". Value in Health. DOI: https://doi.org/10.1016/j.jval.2022.02.008

Rowen D, Mukuria C, Powell P A, Wailoo A. "Exploring the issues of valuing child and adolescent health states using a mixed sample of adolescents and adults". PharmacoEconomics, Accepted: 24 January 2022, Online 16/03/2022.

Laura A Gray, Monica Hernandez Alava and Allan J Wailoo (2021) Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. BMC Cancer 21:1237 DOI: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08964-5

A review of the psychometric performance of selected child and adolescent preference-based measures used to generate utility values for children. Value in Health 2020; ISSN 1098-3015; DOI: https://doi.org/10.1016/j.jval.2020.09.012

J Hill, D Rowen, R Pennington, A Wailoo, R Wong (2020) A review of the methods used to generate utility values in NICE technology assessments for children and adolescents. Value in Health, 2020, 23(7): 907-917. DOI: https://doi.org/10.1016/j.jval.2020.02.011

EQ5DMAP: A command for mapping between 3-level and 5-level EQ-5D (August 2018). To install the command within Stata use "ssc install eq5dmap".

The impact of moving from EQ-5D-3L to -5L in NICE Technology Appraisals (August 2018).

EQ-5D-5L versus EQ-5D-3L: The impact on cost-effectiveness in the United Kingdom (October 2017).

S E Grimm, M Strong, A Brennan et al. (January 2016) Framework for analysing risk in health technology assessments and its application to managed entry agreements (PDF, 1.5MB).

S E Grimm, M Strong, A Brennan et al. (2017) The HTA risk analysis chart: Visualising the need for and potential value of managed entry agreements in health technology assessment. PharmacoEconomics 35: 1287.

M Hernández Alava, A Wailoo. ALDVMM: A command for fitting adjusted limited dependent variable mixture models to EQ-5D. The Stata Journal 2015 In press. Available online.

B Pennington, S Davis (December 2014) Mapping from the health assessment questionnaire to the EQ-5D: The impact of different algorithms on cost-effectiveness results. Value in Health 17(8):762-771.

K K Shah, A Tsuchiya, A Wailoo (2015) Valuing health at the end of life: A stated preference discrete choice experiment. Social Science and Medicine; 124:48-56 (first published online November 2014).

M Hernández Alava, A Wailoo, F Wolfe, K Michaud (2014) A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Medical Decision Making; 34: 919-930 (first published online 2013 DOI: 10.1177/0272989X13500720).

O Ciani, S Davis, P Tappenden, R Garside, K Stein, A Cantrell, E D Saad, M Buse, R S Taylor (2014) Validation of surrogate endpoints in advanced solid tumors: Systematic review of statistical methods, results, and implications for policy makers. International Journal of Technology Assessment in Health Care; 30(3): 312-324.

K K Shah, A Tsuchiya, A Wailoo (2014) Valuing health at the end of life: An empirical study of public preferences. European Journal of Health Economics; 15(4): 389-399 (first published online May 2013; DOI: 10.1007/s10198-013-0482-3).

B Kearns, R Ara, A Wailoo, A Manca, M Hernandez Alava, K Abrams, M Campbell (2013) Good practice guidelines for the use of statistical regression models in economic evaluations. PharmacoEconomics; 31(8): 643-652.

P Thokala, A Duenas (2012) The applicability of multi criteria decision analysis for health technology assessment. Value in Health; 15(8): 1172-1181.

S Davis, A Wailoo (2013) A review of the psychometric performance of the EQ-5D in people with urinary incontinence. Health and Quality of Life Outcomes; 11(20).

K K Shah, A Tsuchiya, A Wailoo. Valuing health at the end of life: An exploratory preference elicitation study (PDF, 364KB). HEDS Discussion Paper 11/17.

J Morden, P Lambert, N Latimer, K Abrams, A Wailoo (2011) Assessing methods for dealing with treatment switching in randomised clinical trials: A simulation study BMC Medical Research Methodology; Vol 11:4.

A Wailoo, A Tsuchiya, C McCabe (2009) Weighting must wait: Incorporating equity concerns into cost-effectiveness analysis may take longer than expected. PharmacoEconomics; 27(12): 983-989.

A Wailoo, A Sutton, N Cooper, D Turner, K Abrams, A Brennan, K Nicholson (2008) Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value in Health; 11(2): 160-171.

Technical support documents

Population adjustment

D Phillipo, A Ades, S Dias, S Palmer, K Abrams, N Welton (February 2018) Methods for population-adjusted indirect comparisons in health technology appraisals. Med Decis Making; 38(2): 200-211. DOI: 10.1177/0272989X17725740

Evidence synthesis

S Dias, N Welton, A Sutton, A Ades (July 2013) Evidence synthesis for decision making 1: Introduction. Med Decis Making; 33: 597-606. DOI: 10.1177/0272989X13487604

S Dias, A Sutton, A Ades, N Welton (July 2013) Evidence synthesis for decision making 2: A Generalised linear modeling framework for pairwise and network meta-analysis of randomised controlled trials. Med Decis Making; 33: 607-617, first published on October 26, 2012. DOI: 10.1177/0272989X12458724

S Dias, A Sutton, N Welton, A Ades (July 2013) Evidence synthesis for decision making 3: Heterogeneity-subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making; 33: 618-640, DOI: 10.1177/0272989X13485157

S Dias, N Welton, A Sutton, D Caldwell, G Lu, A Ades (July 2013) Evidence synthesis for decision making 4: Inconsistency in networks of evidence based on randomised controlled trials. Med Decis Making; 33: 641-656. DOI: 10.1177/0272989X12455847

S Dias, N Welton, A Sutton, A Ades (July 2013) Evidence synthesis for decision making 5: The baseline natural history model. Med Decis Making; 33: 657-670. DOI: 10.1177/0272989X13485155

S Dias, A Sutton, N Welton, A Ades (July 2013) Evidence synthesis for decision making 6: Embedding evidence synthesis in probabilistic cost-effectiveness analysis. Med Decis Making; 33: 671-678. DOI: 10.1177/0272989X13487257

A Ades, D Caldwell, S Reken, N Welton, A Sutton, S Dias (July 2013) Evidence synthesis for decision making 7: A reviewer’s checklist. Med Decis Making; 33: 679-691. DOI: 10.1177/0272989X13485156

Utilities

Papaioannou, J Brazier, S Paisley (2013) Systematic searching and selection of health state utility values from the literature. Value in Health; 16(4): 686-695.

L Longworth, D Rowen (2013) Mapping to obtain EQ-5D utility values for use in NICE Health Technology Appraisals. Value in Health; 16(1): 202-210.

R Ara, A Wailoo (2012) Using health state utility values in models exploring the cost-effectiveness of health technologies. Value in Health; 15: 6.

Survival analysis

N Latimer (2013) Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data. Inconsistencies, limitations, and a practical guide. Medical Decision Making; 33(6): 743-754.

A Bagust, S Beale (2013). Survival analysis and extrapolation modeling of time-to-event clinical trail data for economic evaluation: An alternative approach. Medical Decision Making. DOI: 10.1177/0272989X13497998

N Latimer (2013). Response to “Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: An alternative approach” by Bagust and Beal. Medical Decision Making. DOI: 10.1177/0272989X13511302

Methods Guide update process 2008

A Miners (2008) Estimating ‘costs’ for cost-effectiveness analysis. PharmacoEconomics, 26(9): 745-751.

A Sutton, A E Ades, N Cooper, K Abrams, (2008) Use of indirect and mixed treatment comparisons for technology assessment. PharmacoEconomics, 26(9): 753-767.

M Sculpher (2008) Subgroups and heterogeneity in cost-effectiveness analysis. PharmacoEconomics, 26(9): 799-806.

C McCabe, K Claxton, A J Culyer (2008) The NICE cost-effectiveness threshold. What it is and what that means. PharmacoEconomics, 26(9): 733-744.

K Claxton (2008) Exploring uncertainty in cost-effectiveness analysis. PharmacoEconomics, 26: 781-798.

J Brazier (2008) Valuing health states for use in cost-effectiveness analysis. PharmacoEconomics, 26(9): 769-779.